Dishman Carbogen Amcis Secures NCD Covenant Waivers for FY26 Flexibility

Dishman Carbogen Amcis Ltd. announced on March 31, 2026, that its debenture trustee, Axis Trustee Services Limited, has granted consent for amendments to key financial covenants for its ₹50 crore Non-Convertible Debentures (NCDs). These waivers are for the fiscal year ending March 31, 2026. The move provides the company with increased financial flexibility and allows for a more conservative approach to covenant testing amid external challenges.

Details of the Waiver

The waivers cover the Total Net Debt to EBIDTA covenant, previously set at 4 times, and the Adjusted Debt Service Coverage Ratio covenant, required at a minimum of 1.15x. The Net Debt to Tangible Net Worth covenant remains unchanged at 1.75 times.

Why This Matters for Financial Health

Securing waivers on debt covenants is crucial for maintaining financial maneuverability, particularly when facing volatile market conditions or potential impacts on earnings. It reduces the immediate risk of covenant breaches, offering management breathing room to navigate operational challenges.

Company Background and Focus

Dishman Carbogen Amcis, founded in 1983, evolved into a global Contract Development and Manufacturing Organization (CDMO) through the strategic acquisition of Swiss firm CARBOGEN AMCIS in 2006, creating an integrated entity by 2016. The company has consistently invested in quality, as shown by recent successful USFDA inspections with zero observations at its Naroda and Bavla facilities in June 2025. Dishman Carbogen Amcis has also strategically shifted its focus toward higher-margin segments like Highly Potent APIs (HPAPIs) and oncology projects.

Impact on Operations and Investors

Shareholders can take assurance that the company has secured headroom on its debt obligations for FY26. This allows management to concentrate more on operational execution rather than immediate covenant compliance pressures. Enhanced financial flexibility may also support strategic decisions or buffer against short-term market volatility. The risk of default due to covenant breaches for these specific NCDs is thus mitigated for the current fiscal year.

Ongoing Risks to Monitor

However, several risks remain. Exchange rate fluctuations could lead to translation losses, impacting EBITDA and increasing debt figures. Geopolitical issues, tariffs, and potential loss of market share might cause customer deferrals, affecting standalone performance and requiring production rescheduling. While covenants are waived for FY26, the underlying operational challenges impacting standalone performance persist.

Competitive Landscape

Dishman Carbogen Amcis operates in the competitive CDMO and API manufacturing space. Key Indian peers include Laurus Labs Ltd, Neuland Laboratories Ltd, and Piramal Enterprises Ltd, which also compete on cost and regulatory compliance. Global players like Lonza Group possess extensive manufacturing capacities.

Key Metrics and Covenants

The company's total NCD issue size stands at ₹50.00 crore. The waivers for Total Net Debt to EBIDTA and Adjusted Debt Service Coverage Ratio are critical for the current fiscal year.

What to Track Next

Investors will be watching the company's standalone financial performance amidst ongoing geopolitical and market challenges. They will also observe how management utilizes the enhanced financial flexibility. Tracking any updates on customer deferrals or off-take schedules impacting production plans, and signs of improved EBITDA despite potential currency translation pressures, will be important.